Abstract: A serological detection system and a serological method of detecting a specific immunoglobulin (Ig) isotype against a target antigen in a sample, the serological detection system comprising: (a) a first probe having a first tag, the first probe having general binding affinity for all Ig having the same isotype as the specific Ig isotype in the sample, (b) a second probe having a second tag, the second probe being the target antigen of the specific Ig isotype in the sample, (c) a third tag, the third tag having binding affinity for the first tag and for the second tag so as to form a reporter complex in the presence of the specific IgG antibodies, and (d) a suitable substrate that generates an optically detectable signal in the presence of the reporter complex. In aspects, the serological detection system and the serological method are quantifiable.

Abstract: A system and method for detecting interactions between a first protein or fragment thereof (bait protein) and a second protein or fragment thereof (prey protein) comprising: (a) a bait construct comprising the bait protein, a first epitope tag and an intein N-terminal fragment (IN); and (b) a prey construct comprising the prey protein, a second epitope tag, and an intein C-terminal fragment (IC).

Abstract: Methods of inhibiting mutant EGFR and methods of treating a subject afflicted with a lung cancer having a mutant EGFR, having for example a C797 mutation, are described. The methods comprise administering to a cell or a subject in need thereof a therapeutically effective amount of a compound selected from 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)-2H-chromen-2-one and a structurally related analog thereof; midostaurin; and AZD7622 and a structurally related analog thereof; and mixtures thereof. Compositions and combinations comprising the compounds of the disclosure as well as uses are also provided.

Abstract: Methods of inhibiting mutant EGFR and methods of treating a subject afflicted with a lung cancer having a mutant EGFR, having for example a C797 mutation, are described. The methods comprise administering to a cell or a subject in need thereof a therapeutically effective amount of a compound selected from 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)-2H-chromen-2-one and a structurally related analog thereof; midostaurin; and AZD7622 and a structurally related analog thereof; and mixtures thereof. Compositions and combinations comprising the compounds of the disclosure as well as uses are also provided.

Abstract: Methods of inhibiting mutant EGFR and methods of treating a subject afflicted with a lung cancer having a mutant EGFR, having for example a C797 mutation, are described. The methods comprise administering to a cell or a subject in need thereof a therapeutically effective amount of a compound selected from 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)-2H-chromen-2-one and a structurally related analog thereof; midostaurin; and AZD7622 and a structurally related analog thereof; and mixtures thereof. Compositions and combinations comprising the compounds of the disclosure as well as uses are also provided.

Abstract: The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments. The reconstituted ubiquitin is then cleaved by human ubiquitin proteases resulting in the release of an artificial transcription factor, which in turn activates a reporter gene transcription. Activation of the reporter gene is indicative of the interaction between the two proteins.

Abstract: The present invention is concerned with a method and a kit for detecting an interaction between a first membrane bound test protein or fragment thereof and a second test protein or fragment thereof which is either membrane bound or soluble with an in vivo genetic system based in yeast, bacterial or mammalian cells. The system makes use of the reconstitution of the split ubiquitin protein.

Abstract: The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments. The reconstituted ubiquitin is then cleaved by human ubiquitin proteases resulting in the release of an artificial transcription factor, which in turn activates a reporter gene transcription. Activation of the reporter gene is indicative of the interaction between the two proteins.

Abstract: The present invention is concerned with a method and a kit for detecting an interaction between a first membrane bound test protein or fragment thereof and a second test protein or fragment thereof which is either membrane bound or soluble with an in vivo genetic system based in yeast, bacterial or mammalian cells. The system makes use of the reconstitution of the split ubiquitin protein.